Current Views on the Treatment Algorithm in Patients with Diabetes Mellitus and Erectile Dysfunction

N.V. Pasyechko, T.I. Krytskyy, Naumova L.V., M.A. Dzhula, V.M. Kulchinska

Abstract


Diabetes mellitus (DM) is common throughout the world. According to the World Health Organization’s data, there are about 415 millions of patients with DM now in the world, and their number is growing significantly. The same trend is typical for Ukraine, where the number of patients is more than 1 million. According to chronic incurable course of DM and increase of patients’ life expectancy, research, aimed at studying various organs and systems, and, in particular, sexual function in men, are important. In recent years, significant progress was achieved in understanding the diagnosis and effective treatment of sexual dysfunction. However, disorders of sexual function in patients with DM, which significantly reduce the quality of their lives, remain undetected for a long time due to the fact that patients often do not complain of sexual dysfunction. It should be noted, that even the thoughts of these disorders impair the mental state of patients, which, in turn, leads to worsening the carbohydrate metabolism. Thus, active detection and study of the nature of erectile dysfunction in patients with DM will let not only choose reasonably the methods of treatment for diabetic patients that will enhance their quality of life, but will also allow to pursue the prevention of other neurogenic and vascular complications of underlying disease more efficient. Also, the development of the health care system for men with impaired sexual dysfunction is equally important.


Keywords


diabetes mellitus; erectile dysfunction; diabetes mellitus; glycated hemoglobin

References


Luchytsky VE. Treatment of erectile disfunction in male patients with type 2 diabetes mellitus. International Journal of Endocrinology. 2015;8(72):95-101. (Ukrainian)

Väätäinen S, Keinänen-Kiukaanniemi S, Saramies J. et al. Quality of life along the diabetes continuum: A cross-sectional view of health-related quality of life and general health status in middleaged and older Finns. Qual. Life Res. 2014;23:1935-1944.

Porojan M, Poanta L, Dumitrascu DL. Assessing health related quality of life in diabetic patients. Rom. J. Intern. Med. 2012;50:27-31.

Malavige LS, Levy JC. Erectile dysfunction in diabetes mellitus. J. Sex. Med. 2009;6:1232-1247.

De Berardis G, Franciosi M, Belfiglio M. et al. Erectile dysfunction and quality of life in type 2 diabetic patients: A serious problem too often overlooked. Diabetes Care. 2002;25:84-91.

Yamaguchi Y, Kumamoto Y. Etiological analysis of male diabetic erectile dysfunction with particular emphasis on findings of vascular and neurological examinations. Nippon Hinyokika Gakkai Zasshi. 1994;85:1474- 1483.

Corona J, Mannucci E, Petrone L. et al. NCEP-ATPIII – defined metabolic syndrome, type 2 diabetes mellitus, and prevalence of hypogonadism in male patients with sexual dysfunction. J. Sex. Med. 2007;4:1038-1045.

The Real-Life Safety and Efficacy of Varenafil (REALISE) – Subgroup analysis of patients with cardiovascular diseases, diabetes mellitus or hypertension. J. Sex. Med. 2006;3(3):25.

Hellsten Y, Nyderg M, Jensen LG, Mortensen SP. Vasodilator interaction in skeletal muscle blood flow regulation. J. Physiol. 2012;590:6297-6305.

Santi D, Giannetta E, Isidori A. et al. Effects of chronic use of phosphodiesterase inhibitors on endothelial markers in type 2 diabetes mellitus: a meta-analysis. Eur. J. Endocrinol. 2015;172:103-114.

Balhara YP, Sarkar S, Gupta R. Phosphodiesterase 5 inhibitors for erectile dysfunction in patients with diabetes melliyus: A systematic review and meta-analysis of randomized controlled trials. Indian J. Endocr. Metab. 2015;19:451- 461.

Setter SM, Iltz JL, Fincham JE. et al. Phosphodiesterase 5 inhibitors for erectile dysfunction. Ann. Pharmacother. 2005;39:1286-1295.

Kuthe A. Phosphodiesterase 5 inhibitors in male sexual dysfunction. Curr. Opin. Urol. 2005;13:405-410.

Morano S. Pathophysiology of diabetic sexual dysfunction. J. Endocrinol. Invest. 2003;26(3):65-69.

Guidelines on male sexual dysfunction: erectile dysfunction and premature ejaculation. EAU, 2014.

International Diabetes Federation . IDF Diabetes Atlas. 7th edition. Brussels, Belgium: International Diabetes Federation; 2015.

Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27(5):1047–1053.

Rahman S, Rahman T, Ismail AA, Rashid AR. Diabetes-associated macrovasculopathy: pathophysiology and pathogenesis. Diabetes Obes Metab. 2007;9(6):767–780.

Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol. 1994;151(1):54–61.

Penson DF, Latini DM, Lubeck DP, Wallace KL, Henning JM, Lue TF, Comprehensive Evaluation of Erectile Dysfunction (ExCEED) database Do impotent men with diabetes have more severe erectile dysfunction and worse quality of life than the general population of impotent patients? Results from the Exploratory Comprehensive Evaluation of Erectile Dysfunction (ExCEED) database. Diabetes Care. 2003;26(4):1093–1099.

Lu CC, Jiann BP, Sun CC, Lam HC, Chu CH, Lee JK. Association of glycemic control with risk of erectile dysfunction in men with type 2 diabetes. J Sex Med. 2009;6(6):1719–1728.

Enzlin P, Rosen R, Wiegel M, et al. DCCT/EDIC Research Group Sexual dysfunction in women with type 1 diabetes: long-term findings from the DCCT/EDIC study cohort. Diabetes Care. 2009;32(5):780–785.

Giugliano F, Maiorino M, Bellastella G, Gicchino M, Giugliano D, Esposito K. Determinants of erectile dysfunction in type 2 diabetes. Int J Impot Res. 2010;22(3):204–209.

Esposito K, Maiorino MI, Bellastella G, Giugliano F, Romano M, Giugliano D. Determinants of female sexual dysfunction in type 2 diabetes. Int J Impot Res. 2010;22(3):179–184.

Lewis RW, Fugl-Meyer KS, Corona G, et al. Definitions/epidemiology/risk factors for sexual dysfunction. J Sex Med. 2010;7(4 Pt 2):1598–1607.

De Berardis G, Pellegrini F, Franciosi M, et al. QuED Study Group Clinical and psychological predictors of incidence of self-reported erectile dysfunction in patients with type 2 diabetes. J Urol. 2007;177(1):252–257.

Turek SJ, Hastings SM, Sun JK, King GL, Keenan HA. Sexual dysfunction as a marker of cardiovascular disease in males with 50 or more years of type 1 diabetes. Diabetes Care. 2013;36(10):3222–3226.

Araujo AB, Travison TG, Ganz P, et al. Erectile dysfunction and mortality. J Sex Med. 2009;6(9):2445–2454.

Thorve VS, Kshirsagar AD, Vyawahare NS, Joshi VS, Ingale KG, Mohite RJ. Diabetes-induced erectile dysfunction: epidemiology, pathophysiology and management. J Diabetes Complications. 2011;25(2):129–136.

Corona G, Giorda CB, Cucinotta D, Guida P, Nada E, Gruppo di studio SUBITO-DE The SUBITO-DE study: sexual dysfunction in newly diagnosed type 2 diabetes male patients. J Endocrinol Invest. 2013;36(10):864–868.

Rosen RC, Wing RR, Schneider S, et al. Erectile dysfunction in type 2 diabetic men: relationship to exercise fitness and cardiovascular risk factors in the Look AHEAD trial. J Sex Med. 2009;6(5):1414–1422.

Chew SKh, Taouk Y, Xie J, et al. Relationship between diabetic retinopathy, diabetic macular oedema and erectile dysfunction in type 2 diabetics. Clin Experiment Ophthalmol. 2013;41(7):683–689.

Malavige LS, Levy JC. Erectile dysfunction in diabetes mellitus. J Sex Med. 2009;6(5):1232–1247.

Isidori AM, Buvat J, Corona G, et al. A critical analysis of the role of testosterone in erectile function: from pathophysiology to treatment – a systematic review. Eur Urol. 2014;65(1):99–112.

Wessells H, Penson DF, Cleary P, et al. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group Effect of intensive glycemic therapy on erectile function in men with type 1 diabetes. J Urol. 2011;185(5):1828–1834.

Khatana SA, Taveira TH, Miner MM, Eaton CB, Wu WC. Does cardiovascular risk reduction alleviate erectile dysfunction in men with type II diabetes mellitus? Int J Impot Res. 2008;20(5):501–506.

Konstantinos G, Petros P. Phosphodiesterase-5 inhibitors: future perspectives. Curr Pharm Des. 2009;15(30):3540–3551.

Vardi M, Nini A. Phosphodiesterase inhibitors for erectile dysfunction in patients with diabetes mellitus. Cochrane Database Syst Rev. 2007:CD002187.




DOI: https://doi.org/10.22141/2224-0721.8.80.2016.89544

Refbacks

  • There are currently no refbacks.


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© "Publishing House "Zaslavsky", 1997-2017

 

 Яндекс.МетрикаSeo анализ сайта Рейтинг@Mail.ru